Related Experiment Video

Updated: Jan 9, 2026

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

5.2K

Antiestrogens: future prospects

A Howell1

  • 1Christie Hospital N.H.S. Trust, Department of Medical Oncology, Manchester, United Kingdom.

Oncology (Williston Park, N.Y.)
|February 1, 1997
PubMed

Insights

New antiestrogen therapies are being developed to improve upon tamoxifen for breast cancer treatment. These agents show promise with enhanced estrogen receptor binding and antitumor activity compared to tamoxifen.

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Tamoxifen is the standard endocrine therapy for early and advanced breast cancer.
  • Research is ongoing to develop more effective antiestrogen therapies.
  • Improving therapeutic efficacy is a key goal in breast cancer treatment.

Purpose of the Study:

  • To review novel antiestrogen compounds.
  • To compare their efficacy with tamoxifen.
  • To discuss preclinical and clinical data of these agents.

Main Methods:

  • Review of existing literature on antiestrogen compounds.
  • Comparison of preclinical and clinical data.
  • Analysis of estrogen-receptor binding affinity and antitumor activity.

Main Results:

  • Several novel nonsteroidal and steroidal antiestrogens have been developed.
  • Some agents demonstrate improved estrogen-receptor binding affinity.
  • Enhanced antiestrogenic and antitumor activity compared to tamoxifen is observed in some compounds.

Conclusions:

  • New antiestrogen agents offer potential improvements over tamoxifen.
  • Further clinical development is warranted for these promising therapies.
  • These agents represent a significant advancement in endocrine therapy for breast cancer.

More Related Videos

Prospecting Microbial Strains for Bioremediation and Probiotics Development for Metaorganism Research and Preservation09:49

Prospecting Microbial Strains for Bioremediation and Probiotics Development for Metaorganism Research and Preservation

Published on: October 31, 2019

23.1K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.3K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
424
Menopause01:28

Menopause

Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
3.5K